Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Personnel

John Potthoff Joins RQM+ as CEO


RQM+, a leading global MedTech contract research organization (CRO), today announced John Potthoff, Ph.D., as its new CEO. This transition comes as former CEO, Margaret Keegan, announced she plans to move out of day-to-day operations to focus on her role as an operating partner with Linden Capital Partners. Margaret will remain on the board of RQM+.

John, co-founder and former CEO of Elligo Health Research®, has been on the RQM+ board since 2021. He brings extensive MedTech industry expertise to his new role as CEO of RQM+. Prior to Elligo, he was CEO of Theorem Clinical Research, which had a significant global med device and diagnostics business unit, and was also the chief operating officer at INC Research.

"During Margaret's tenure, she completed three acquisitions and made significant progress in creating an end-to-end MedTech CRO at RQM+," John said. "I look forward to building on this remarkable foundation and continuing to drive growth and advance global healthcare through MedTech innovation."

As a board member of RQM+, Margaret will continue to assist the company in executing its core priorities. "I am extremely proud of the RQM+ team's many accomplishments," she said. "While I'll be stepping away from day-to-day operations, I look forward to continuing to support the company. I believe John is a proven leader and is very knowledgeable about the company and our industry. He is well-positioned to lead and enhance RQM+ to meet the ever-changing MedTech industry needs now and into the future."

About RQM+

RQM+ is a leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle. RQM+'s global team of clinical, technical, and industry experts push the boundaries of excellence. With former FDA, Medicines, and Healthcare Products Regulatory Agency (MHRA) and notified body regulators, RQM+ has deep expertise in all clinical specialties. We reduce commercialization risk by offering a full complement of CRO services to progress medical devices, digital therapeutics and diagnostics onto the market and keep them there. In addition to early- and mid-stage MedTech companies, we currently work with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies.


These press releases may also interest you

at 06:32
Enhancing Healthcare: A Global Market Study of Medical Robotics and Computer-Assisted Surgery
"According to the latest BCC Research study, the demand for Medical Robotics and Computer-assisted Surgery: The Global Market is expected to grow from $11.5 billion in 2023 and is projected to reach $19.5 billion by the end of 2028, at a compound...

at 06:15
Karmanos Welcomes Wasif Saif, M.D., to Lead Phase 1 Clinical Trials
The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team...

at 06:07
Seed Health to Present New Clinical Data on 'DS-01® Daily Synbiotic' for Both Antibiotic Recovery and IBS at Digestive Disease Week 2024
Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two...

at 06:05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals, Inc. today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS)...

at 06:00
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel...

at 06:00
Study at Japan's Kameda Medical Center Demonstrates Excellent Outcomes for Ibex's AI-powered Solution in Diagnosing Prostate and Breast Cancer
Ibex Medical Analytics (Ibex), a global leader in AI-powered cancer diagnostics, and Kameda Medical Center (Kameda), a leading Japanese institute at the pinnacle of healthcare innovation, today announced the publication of a clinical study evaluating...

More news about Health...


News published on and distributed by: